Text Size Normal Text Sizing Button Medium Text Sizing Button Large Text Sizing Button Text Contrast Normal Contrast Button Reverse Contrast Button Switch to Spanish Language Contact Us Sitemap Sign In Register
Link to Homepage About AHAF
Donate Now Get Involved  
Alzheimer's Disease Research Macular Degeneration Research National Glaucoma Research


Sign up for Email Notifications
If you would like to be notified when submission deadlines are announced please click on the link below.

Sign up for new RFP announcements and submission deadline notifications.

This email list is not sold or distributed, and serves only as an annual reminder of the availability of research funding through the American Health Assistance Foundation (www.ahaf.org). Please follow instructions on the notification emails for removal requests.
 
AHAF Research Grants Funding
Grant Funding for Alzheimer's Research
Grant Funding for Macular Degeneration Research
Grant Funding for Glaucoma Research
 

  

Alzheimer's Disease Research - Completed Award

Photo Pending

Lee Goldstein, M.D., Ph.D.

Brigham and Women's Hospital
Boston, MA

Title: NonInvasive Laser Technology for Alzheimer's Diagnosis
Non-Technical Title:

Duration: April 1, 2006 - March 31, 2008
Award Type:
Award Amount: $300,000

Details:

A major roadblock in AD research, treatment and drug development is the lack of a safe and reliable diagnostic test. Definitive diagnosis currently involves analysis of brain tissue after death. A sensitive early diagnostic test would greatly speed testing of new drugs in animal and human treatment trials. Building on his exciting recent discoveries (Goldstein et al., Lancet, 2003) that Alzheimer's disease (AD) can be detected in the lens of the eye, Dr. Goldstein’s team has developed new optical tests that can potentially diagnose and monitor the disease from the beginning stages. AD involves the accumulation of a protein called beta amyloid in the brain which also accumulates in the lens of the eye as unusual cataracts in patients with AD. These cataracts are different from those associated with aging. Dr. Goldstein has been able to non-invasively detect these special AD cataracts in humans and in an AD mouse model. His technique uses quasi-elastic light scattering (QLS) to detect cataract formation. This instrument is the most sensitive technology available to detect the very early stages of cataracts. He has also developed a complementary diagnostic technology called fluorescence ligand scanning (FLS). In this approach, he uses special eye drops that contain fluorescent image enhancing molecules that bind to beta amyloid in the lens. If beta amyloid molecules are present, the fluorescing molecules light up and are detected by the instrument. The FLS test is now undergoing evaluation in laboratory animals. The diagnostic tests will accelerate preclinical drug discovery, streamline clinical testing, and facilitate early clinical intervention. Patient care will be greatly enhanced by an objective means to establish early diagnosis, monitor disease progression, and assess treatment response.